Phase 3 Trial Launches for Ifinatamab Deruxtecan in Advanced Prostate Cancer Patients Daiichi Sankyo and Merck have announced the initiation of IDeate-Prostate01, a global Phase 3 clinical trial evaluating the investigational drug ifinatamab deruxtecan (I-DXd) in patients with metastatic castration-resistant…
FDA Approves KEYTRUDA® (Pembrolizumab) for Perioperative Treatment of Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma Merck known as MSD outside the United States and Canada, recently announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA®…
Novartis’ Fabhalta Shows Meaningful Hemoglobin Improvement in PNH Patients, Reinforcing Benefit of Oral Monotherapy Novartis recently announced positive results from its APPULSE-PNH study — a Phase IIIB trial evaluating Fabhalta® (iptacopan) in adult patients with paroxysomal nocturnal hemoglobinuria (PNH) who…
Otsuka Unveils Promising Phase 3 Results for Sibeprenlimab in IgA Nephropathy, Marking Significant Proteinuria Reduction and Advancing a Novel APRIL-Targeted Therapy Otsuka Pharmaceutical Development & Commercialization, Inc., in collaboration with Otsuka Pharmaceutical Co., Ltd., has announced encouraging interim findings from…
Genmab Unveils Promising Phase 1/2 Data for Rina-S® in Heavily Pretreated Advanced Endometrial Cancer at ASCO 2025 Genmab A/S, a leading biotechnology company specializing in antibody-based therapies for cancer, has announced new clinical data from the Phase 1/2 RAINFOL™-01 trial…
Biogen and City Therapeutics Forge Strategic Partnership to Pioneer Next-Generation RNAi-Based Therapies Targeting Central Nervous System Diseases Biogen,a global leader in neuroscience and neurodegenerative disease research, and City Therapeutics, Inc., a private biopharmaceutical company at the forefront of RNA interference…
Merck Highlights Breakthrough Innovations in Advanced Cancers and Rare Tumors at ASCO 2025 Merck, a global leader in science and technology, has once again showcased its commitment to transforming cancer care through the presentation of groundbreaking clinical data across a…
AbbVie Gains First Solid Tumor FDA Approval With EMRELIS™ for High c-Met Overexpressing Advanced NSCLC AbbVie has achieved a key milestone in its oncology pipeline with the announcement that the U.S. Food and Drug Administration (FDA) has granted accelerated approval…
Feinstein Institutes Study Vagus Nerve Stimulation for Obesity Obesity is one of the most pressing health challenges facing the modern world, with over a third of the global population affected by excess weight. This complex and multifactorial condition contributes to…
Ten-Year Data Perjeta Regimen Cuts Death Risk by 17% in HER2+ Breast Cancer In a significant milestone for the treatment of early-stage HER2-positive breast cancer, Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), together with the…
Azafaros Raises €132M in Series B to Advance Phase 3 LSD Therapies Azafaros, a clinical-stage biotechnology company with a specialized focus on rare lysosomal storage disorders (LSDs), announced the successful completion of a €132 million ($142 million USD equivalent) Series…
A global healthcare company today announced positive top-line results from its Phase 3 clinical trial (NCT05139121) evaluating the contraceptive efficacy and safety of XULANE LO, an investigational low-dose weekly transdermal patch delivering 150 mcg norelgestromin and 17.5 mcg ethinyl estradiol…